Oslo, November 7, 2001

Nutri Pharma ASA (OSE: NUT) announces the filing in the European Patent Office (EPO) of an opposition to its granted European patent, directed to Nutri Pharma’s proprietary technology for combining soy proteins, fibres and lipids. Nutri Pharma’s issued U.S. patents, are unaffected by the filing.

In accordance with opposition procedures, Nutri Pharma will defend its granted European patent before the Opposition Division (OD) of the EPO.

"Given the recognised commercial importance of Nutri Pharma's patented technology, the filing of an opposition was not unexpected," said Graham Waters, Chief Executive of Nutri Pharma.

Nutri Pharma's IP portfolio comprises a total of 12 patent-families and applications, and with a total of around 750 claims. The filing of an opposition concerns 1 of these patent-families.

Nutri Pharma is one of the global leaders in functional foods and beverages, developing and marketing innovative functional food ingredients and products, all based on the Company’s proprietary soy technology. The products cure and prevent lifestyle-related diseases, such as elevated cholesterol level, obesity and type 2 diabetes. Nutri Pharma is listed on the main list at the Oslo Stock Exchange. Nutri Pharma has offices in Norway, Denmark, Sweden, USA, the UK and Germany and a representative office in Sidney, Australia

For further information, please contact:

Graham Waters, CEO Nutri PharmaTEL: +44 7900 582 022